11 / 11
PCOS 2018
Journal of Clinical and Molecular Endocrinology
ISSN: 2572-5432
Page 28
June 07-08, 2018
London, UK
4
th
World Congress on
Polycystic Ovarian
Syndrome
P
olycystic ovarian syndrome (PCOS) is the most prevalent
endocrinopathy during the reproductive years, affecting
5%–10% of women, and has been classically associated with
ovulatory dysfunction and hyperandrogenism. In 2003, an
expert conference was organized in Rotterdam, resulting in
revised criteria for making the diagnosis of PCOS using two of
the following three features: 1) oligo- or anovulation; 2) signs
of hyperandrogenism; and 3) ultrasound evidence of polycystic
ovaries. PCOS has a genetic multifactorial inheritance and
is associated with a high risk of insulin resistance. Women
with PCOS are at increased risk for reproductive and medical
complications, including infertility as well as the metabolic
syndrome, a ubiquitous pathologic constellation of diseases that
place patients at a risk of significant morbidity and mortality. The
metabolic syndrome includes abdominal obesity, dyslipidemia,
hypertension and pre-diabetes, and occurs at an increased
overall prevalence rate of 43%–47% in women with PCOS. The
National Cholesterol Education Program–Adult Treatment Panel
defines the metabolic syndrome based upon three of the five
following factors: waist circumference, fasting serum glucose,
fasting serum triglycerides, serum HDL-cholesterol and blood
pressure. Further, PCOS patients are significantly predisposed to
prediabetes and type 2 diabetes. Metformin is an oral biguanide
insulin-sensitizing agent, commonly used to maintain blood
glucose control in diabetes and also has a role in menstrual
regulation, pregnancy and ameliorating the metabolic syndrome.
In this seminar, the association between the metabolic syndrome
and PCOS will be reviewed, as well as evidence based medical
therapies and non-pharmacologic therapies to reduce medical
complications and improve well-being will be outlined.
Biography
Mark P Trolice, M.D., FACOG, FACS, FACE is the Director of Fertility CARE
(Center of Assisted Reproduction & Endocrinology) as well as Clinical As-
sociate Professor in the Department of Obstetrics & Gynecology (OB/GYN)
at the University of Central Florida College of Medicine in Orlando. He is the
past President of the Florida Society of Reproductive Endocrinology & In-
fertility (REI) and Central Florida OB/GYN Society as well as past Division
Director of (REI) at Winnie Palmer Hospital, part of Orlando Health. He is
double Board-certified in REI and OB/GYN and has been awarded the Ameri-
canMedical Association’s “Physicians’ Recognition Award” annually. He was
honored as one among the top 5% of doctors in the U.S. He has authored
research studies with publications in many leading medical journals and
textbooks. He has lectured at numerous physician conferences and patient
seminars around the country. In addition he participated in TV news/talk
shows, radio, webcasts and newspapers. He is on the Editorial Boards of
The Female Patient and OBG Management, and former Advisory Board of
Conceive Magazine and Medical Advisory Council of The American Fertility
Association. His current book entitled, “Get Pregnant! Science-based strat-
egies to help you finally overcome infertility and have your baby” is due for
release in the Fall of 2019.
drtrolice@theivfcenter.comPolycystic ovarian syndrome (PCOS): It’s not just about
fertility
Mark P Trolice
Fertility CARE: The IVF Center, Orlando, FL, USA
Mark P Trolice, J Clin Mol Endocrinol 2018, Volume 3
DOI: 10.21767/2572-5432-C1-002